As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage.
By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a company working in healthcare, with a specific emphasis on Johnson & Johnson’s sectors: consumer, medical device and pharmaceuticals.
he most commonly diagnosed cancer and the leading cause of cancer death worldwide, is lung cancer.* With nearly 2 million deaths last year alone, the immense unmet need to catch and stop this disease in its tracks, or prevent it from occurring in the first place, is inspiring potential breakthrough innovations worldwide. From next generation immunotherapies to targeting genetic causes of the disease – impactful initiatives to prevent and intercept lung cancer are on the horizon.
Johnson & Johnson Innovation, JLABS and Janssen is convening experts and innovators in the field to present on and create dialogue around the core challenges faced by innovators in the field, new discoveries, emerging technologies, and progressive solutions. This program will provide the opportunity to network with the innovation community, learn from experts and cultivate relationships in the lung cancer space.
This program is part of the Johnson & Johnson Lung Cancer Initiative, which aims to accelerate innovation in the prevention, interception and curing of lung cancer to ultimately eliminate the disease.
9:30am | Registration opens; Networking & coffee
10:00am | Introduction
10:10am | Researcher/leader Presentation 1
10:40pm | Break
11:00am | Innovator presentation 1
11:15am | Innovator presentation 2
11:30am | Innovator presentation 3
11:45am | Panel discussion
12:30am | Closing remarks & networking lunch begins
01:30pm | Program close
Matthew Lorenzi, PhD | Vice President | Solid Tumor Targeted Therapy Disease Area at The Janssen Pharmaceutical Companies of Johnson & Johnson [introduction]
Ravi Salgia, MD, PhD | Medical Oncologist; Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope
Sonya Zabludoff, Ph.D. | Senior Director, Clinical Development, Nitto BioPharma, Inc.
Troy Wilson, PhD, JD | Co-founder, President & CEO, Kura Oncology; Executive Chairman, Wellspring Biosciences
The views expressed during this event by anyone other than an employee of Johnson & Johnson Innovation LLC, its parent company or any affiliate companies (herein after referred to as “JJI”) are those of the speakers or experts alone, and such speakers or experts are solely responsible for the information and opinions expressed by them. By hosting this event and the presentations, JJI does not endorse the views of the speakers, experts or the attendees, and JJI makes no warranties, express or implied, as to the content, the views, advice or the information presented.